Becton, Dickinson and Company $BDX Shares Sold by Notis McConarty Edward

Notis McConarty Edward decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 79.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,790 shares of the medical instruments supplier’s stock after selling 7,116 shares during the quarter. Notis McConarty Edward’s holdings in Becton, Dickinson and Company were worth $308,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of BDX. GQG Partners LLC acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at $689,833,000. Vanguard Group Inc. raised its position in shares of Becton, Dickinson and Company by 4.7% during the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock worth $6,414,322,000 after purchasing an additional 1,259,750 shares during the period. Nuveen LLC purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at $211,097,000. Kingstone Capital Partners Texas LLC purchased a new stake in shares of Becton, Dickinson and Company during the second quarter valued at $155,080,000. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of Becton, Dickinson and Company by 10.8% during the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock valued at $1,567,654,000 after purchasing an additional 667,957 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Activity

In other news, EVP Michael David Garrison sold 1,185 shares of the company’s stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. This represents a 19.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Claire Fraser sold 917 shares of the company’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 3,023 shares of company stock valued at $562,036. 0.36% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Morgan Stanley upped their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Royal Bank Of Canada assumed coverage on Becton, Dickinson and Company in a report on Thursday, September 25th. They set a “sector perform” rating and a $211.00 target price for the company. Piper Sandler reaffirmed a “neutral” rating and set a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday. Finally, Wells Fargo & Company upped their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Three equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average target price of $205.40.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $193.85 on Thursday. The firm has a market cap of $55.56 billion, a P/E ratio of 34.87, a PEG ratio of 1.50 and a beta of 0.25. The stock’s 50-day moving average is $189.65 and its two-hundred day moving average is $186.88. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.28. The company had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm’s revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.1%. The ex-dividend date was Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio is 74.82%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.